Business, energy, technology, markets and global industry news from Business News Today

MaaT013

PharmaDeviceNews MaaT013
Representative image of microbiome-based therapy research as MaaT Pharma advances MaaT013 after pivotal Phase 3 GI-aGvHD data, highlighting the growing regulatory and clinical focus on microbiome therapeutics in transplant medicine.
Pharma & Biotech

MaaT Pharma’s PICASSO trial met its primary goal, so why is the melanoma efficacy picture still uncertain?

MaaT Pharma's PICASSO trial met its safety goal but showed similar melanoma responses. Discover what the results mean for MaaT034.

Read More
Pharma & Biotech

MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test

MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.

Read More
A clinician reviews an investigational treatment as MaaT Pharma prepares to challenge the negative European regulatory opinion on MaaT013 for acute graft-versus-host disease. Representative image.
Pharma & Biotech

MaaT Pharma seeks second review of MaaT013 as regulators question single-arm evidence

Discover why MaaT Pharma is challenging the negative CHMP opinion on MaaT013 and what the September review means for acute graft-versus-host disease.

Read More
Representative image of microbiome-based therapy research as MaaT Pharma advances MaaT013 after pivotal Phase 3 GI-aGvHD data, highlighting the growing regulatory and clinical focus on microbiome therapeutics in transplant medicine.
Pharma & Biotech

Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate

MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.

Read More